Abstract |
Current human immunodeficiency virus type I (HIV) gene therapy strategies focus on rendering HIV target cells non-permissive to viral replication. However, gene-modified cells fail to accumulate in patients and the virus continues to replicate in the unmodified target cell population. We have designed lentiviral vectors encoding secreted anti- HIV proteins to protect both gene-modified and unmodified cells from infection. Soluble CD4 (sCD4), a secreted single chain variable fragment (sscFv(17b)) and a secreted fusion inhibitor (sFI(T45)) were used to target receptor binding, co-receptor binding and membrane fusion, respectively. Additionally, we designed bi- and tri-functional fusion proteins to exploit the multistep nature of HIV entry. Of the seven antiviral proteins tested, sCD4, sCD4-scFv(17b), sCD4-FI(T45) and sCD4-scFv(17b)-FI(T45) efficiently inhibited HIV entry. The neutralization potency of the bi-functional fusion proteins sCD4-scFv(17b) and sCD4-FI(T45) was superior to that of sCD4 and the Food and Drug Administration-approved fusion inhibitor T-20. In co-culture experiments, sCD4, sCD4-scFv(17b) and sCD4-FI(T45) secreted from gene-modified producer cells conferred substantial protection to unmodified peripheral blood mononuclear cells. In conclusion, continuous delivery of secreted anti- HIV proteins via gene therapy may be a promising strategy to overcome the limitations of the current treatment.
|
Authors | A Falkenhagen, M Ameli, S Asad, S E Read, S Joshi |
Journal | Gene therapy
(Gene Ther)
Vol. 21
Issue 2
Pg. 175-87
(Feb 2014)
ISSN: 1476-5462 [Electronic] England |
PMID | 24305417
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-HIV Agents
- Antibodies, Monoclonal
- Biological Products
- CD4 Antigens
- HIV Fusion Inhibitors
- Single-Chain Antibodies
|
Topics |
- Anti-HIV Agents
(pharmacology)
- Antibodies, Monoclonal
(genetics, pharmacology)
- Biological Products
(pharmacology)
- CD4 Antigens
(genetics, pharmacology)
- Cell Line, Tumor
- Genetic Therapy
(methods)
- Genetic Vectors
(administration & dosage)
- HEK293 Cells
- HIV Fusion Inhibitors
(pharmacology)
- HIV-1
(drug effects)
- Humans
- Lentivirus
(genetics)
- Single-Chain Antibodies
(genetics, pharmacology)
- United States
- United States Food and Drug Administration
|